Skip to main content

Epidiolex News (Page 2)

Cannabis-Related Disorder Linked to Risk for Head and Neck Cancer

MONDAY, Aug. 12, 2024 – Cannabis-related disorder is associated with an increased rate of head and neck cancer (HNC), according to a study published online Aug. 8 in JAMA Otolaryngology-Head & Neck...

FDA Approves Epidiolex (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) – GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines,...

FDA Medwatch Alert: FDA, FTC Warn Company Marketing Unapproved Cannabidiol Products with Unsubstantiated Claims to Treat Teething and Ear Pain in Infants, Autism, ADHD, Parkinson’s and Alzheimer’s Disease

October 22, 2019 – Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling...

FDA Approves Epidiolex (cannabidiol) to Treat Lennox-Gastaut Syndrome and Dravet Syndrome

June 25, 2018 – The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy,...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Lennox-Gastaut Syndrome

Epidiolex patient information at Drugs.com